Shattuck Labs Narrows Loss in Fiscal Q2
Shattuck Labs (NASDAQ:STTK), a clinical-stage biotechnology company focused on developing novel immunotherapies, released its second quarter 2025 earnings results on August 14, 2025, which exceeded analyst expectations and marked a substantial improvement from the prior year quarter's GAAP loss of $(0.42) per share. As widely anticipated for a pipeline-driven biotech, the company reported no revenue, in line with forecasts. Spending reductions in both research and development and general expenses contributed to the narrowed loss and marked important pipeline progress, but future results remain tied to clinical and regulatory milestones—especially for its lead antibody program SL-325.
Source: Analyst estimates for the quarter provided by FactSet.
Shattuck Labs is a biotechnology company specializing in the development of biologic drugs called antibodies. These proteins are engineered to modulate the immune system for the treatment of inflammatory and immune-mediated diseases. The company now focuses most of its resources on advancing a single lead pipeline asset: SL-325, an antibody targeting Death Receptor 3 (DR3). This candidate is designed for diseases such as inflammatory bowel disease, driven by immune cell activation and inflammation.
Source Fool.com
